BCL2L1 and prostate cancer: In a detailed study using fisetin, the blocking of Akt by exogenous siRNA in prostate cancer cells (LNCaP) caused an elevated Bad and Bax expression, and decreased expression of Bcl-2 and Bcl-xL, which suggested that these effects are mediated in part through Akt [53].